文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高剂量率近距离放疗、外照射放疗与雄激素剥夺治疗的前瞻性研究:MRI引导方法的10年经验

Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach.
PubMed 文献 · Radiother Oncol · 2023-11-22

前瞻性队列纳入309例中危或高危局限期前列腺腺癌患者,接受单次15 Gy高剂量率近距离放疗联合37.5 Gy/15次外照射放疗,雄激素剥夺治疗时长按风险组决定。中位随访88个月,41例出现生化失败、18例发生远处转移;多因素分析显示MR-T3b期(HR 3.88)与ADT使用(HR 3.99)是生化失败的预测因素,穿刺阳性针数>50%是远处转移的唯一独立预测因素(HR 4.36)。

要点

  • 中位随访88个月,309例中41例生化失败、18例远处转移。
  • MR-T3b期(HR 3.88,p=0.001)与ADT使用(HR 3.99,p=0.03)为生化失败预测因素。
  • 穿刺阳性针数>50%是远处转移的唯一独立预测因素(HR 4.36,p=0.002)。

核心结论

  • mpMRI显示精囊受侵的患者生化复发风险更高,穿刺阳性针数>50%的患者发生前列腺癌转移风险更高。

研究设计与样本

  • 前瞻性队列研究,纳入309例中危(199例)或高危(110例)前列腺腺癌患者。
  • 患者接受单次15 Gy高剂量率近距离放疗联合37.5 Gy/15次外照射放疗,ADT时长按风险组决定。
  • 采用描述性分析、单因素与多因素风险比及Kaplan-Meier模型分析。

主要发现

  • 中位年龄72岁;MRI分期≤T2c占58.3%、T3a占34.1%、T3b占7.6%;ISUP分级1-3占78.9%、4-5占21.1%。
  • 穿刺阳性针数≤50%占71.8%、>50%占28.2%;治疗前PSA中位值9.9 ng/mL。
  • 中位随访88个月,41例出现生化失败,18例发生远处转移。
  • 多因素Cox回归显示MR-T3b期(HR 3.88,p=0.001)与ADT使用(HR 3.99,p=0.03)是生化失败的预测因素。
  • 穿刺阳性针数>50%是远处转移的唯一独立预测因素(HR 4.36,p=0.002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the predictive factors for biochemical failure and distant metastases in a prospective cohort of patients with localized prostate cancer treated with the combination of HDR BT and EBRT. METHODS AND MATERIALS: Patients with intermediate (IR) or high-risk (HR) prostate adenocarcinoma received a single fraction of HDR of 15 Gy combined with RT of 37.5 Gy in 15 fractions. ADT duration was used depending on risk-group. Descriptive analyses were performed. Univariate and multivariate Hazard Ratios were obtained. Finally, the Kaplan-Meier model was used to describe the survival of the events of interest. RESULTS: 309 patients were treated prospectively (199 were IR and 110 HR). Median age was 72 years; 58.3 % were MRI stage ≤ T2c, 34.1 % T3a and 7.6 % T3b; ISUP-grade 1-3 in 78.9 % and ISUP 4-5 in 21.1 %. 71.8 % of patients had ≤ 50 % positive-cores in biopsy and 28.2 % had > 50 %. Median pre-treatment PSA was 9.9 ng/mL. After a median follow-up of 88 months, 41 patients presented biochemical failure and 18 developed distant metastases. Multivariate cox-regression analyses found that MR-T3b Stage (HR 3.88, p = 0.001) and ADT use (HR 3.99, p = 0.03) were the only predictive factors for biochemical failure and the number of positive cores (>50 %) the only independent predictive factor of distant metastases (HR 4.36, p = 0.002). CONCLUSIONS: Patients with mpMRI evidence of invasion of the SV and involvement of more than 50% of the cores in the prostate biopsy are patients with a higher risk of presenting a biochemical recurrence or developing metastasis due to their prostate cancer, respectively.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gomez-Iturriaga A, Zaragoza L, Valverde I, et al. Prospective study of HDR brachytherapy (BT), external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT): 10-years experience of an MRI-guided approach. Radiother Oncol. 2023. PMID: 37995851. doi:10.1016/j.radonc.2023.110024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。